

Freedom of Information Request: 0282

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

Within your trust how many patients have been treated, in the past 6 months January to June 2018 by diagnosed eye condition. Of these patients how many are new to treatment [they have not previously received an injection / implant]? If your trust can not split by condition, please supply the total patients and total new patients. A new patient is one that has not previously received an injection in either eye for an ophthalmology condition.

Please Note: We can provide number of drugs given but cannot break this down to the number of patients or whether these are new or existing patients.

Queen Elizabeth Hospital

01/01/2018 - 30/06/2018	Lucentis (ranibizumab) Injections	Eylea (aflibercept) Injections	bevacizumab, Dexamathasone or Fluocinolone
Total Vials			
/ Implants	100	1,733	434

Heartlands, Good Hope and Solihull Hospital

AFLIBERCEPT 40 mg in 1ml Injection		
BEVACIZUMAB 1.25 mg in 0.05ml Injection		
DEXAMETHASONE 700 microgram Intravitreal		
Implant		
FLUOCINOLONE ACETONIDE 190 microgram	5	
Intravitreal Implant		
RANIBIZUMAB 10 mg in 1ml Pre-Filled Syringe		

Chair: Rt Hon Jacqui Smith Chief Executive: Dame Julie Moore